Clinical Trial Update: Investigating the Safety and Efficacy of SHR6508 Injection in the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients : A Multicenter, Long-term Clinical Trial [Phase 2]

View source ↗

Summary

A multicenter Phase 2 trial evaluating the safety and efficacy of SHR6508 injections for secondary hyperparathyroidism in chronic kidney disease patients on hem…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Hyperparathyroidism

Drugs mentioned

• SHR6508 (SHR6508)

Snippet

Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. | Conditions: Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis | Phase 2 | Status: UNKNOWN